AAK1 Identified as an Inhibitor of Neuregulin-1/ErbB4-Dependent Neurotrophic Factor Signaling Using Integrative Chemical Genomics and Proteomics  by Kuai, Letian et al.
Chemistry & Biology
ArticleAAK1 Identified as an Inhibitor of Neuregulin-1/
ErbB4-Dependent Neurotrophic Factor Signaling
Using Integrative Chemical Genomics and Proteomics
Letian Kuai,1,6 Shao-En Ong,2,7 Jon M. Madison,1 Xiang Wang,2,8 Jeremy R. Duvall,2 Timothy A. Lewis,2
Catherine J. Luce,1 Sean D. Conner,3 David A. Pearlman,1 John L. Wood,4 Stuart L. Schreiber,2 Steven A. Carr,2
Edward M. Scolnick,1 and Stephen J. Haggarty1,5,*
1Stanley Center for Psychiatric Research
2Broad Institute of Harvard and MIT
7 Cambridge Center, Cambridge, MA 02142, USA
3Department of Genetics, Cell Biology and Development, University of Minnesota, 6-160 Jackson Hall, 321 Church Street SE,
Minneapolis, MN 55455, USA
4Department of Chemistry, Colorado State University, Fort Collins, CO 80523, USA
5Center for Human Genetic Research, Massachusetts General Hospital, Department of Neurology, Harvard Medical School,
185 Cambridge Street, Boston, MA 02114, USA
6Present Address: GlaxoSmithKline, 830 Winter Street, Waltham, MA 02142, USA
7Present Address: Department of Pharmacology, University of Washington, School of Medicine, Seattle, WA 98195-7280, USA
8Present Address: Department of Chemistry and Biochemistry, University of Colorado, Boulder, CO 80309, USA
*Correspondence: haggarty@chgr.mgh.harvard.edu
DOI 10.1016/j.chembiol.2011.03.017SUMMARY
Target identification remains challenging for the field
of chemical biology. We describe an integrative
chemical genomic and proteomic approach combin-
ing the use of differentially active analogs of small
molecule probes with stable isotope labeling by
amino acids in cell culture-mediated affinity enrich-
ment, followed by subsequent testing of candidate
targets using RNA interference-mediated gene
silencing.We applied this approach to characterizing
the natural product K252a and its ability to potentiate
neuregulin-1 (Nrg1)/ErbB4 (v-erb-a erythroblastic
leukemia viral oncogene homolog 4)-dependent
neurotrophic factor signaling and neuritogenesis.
We show that AAK1 (adaptor-associated kinase 1)
is a relevant target of K252a, and that the loss
of AAK1 alters ErbB4 trafficking and expression
levels, providing evidence for a previously unrecog-
nized role for AAK1 in Nrg1-mediated neuro-
trophic factor signaling. Similar strategies should
lead to the discovery of novel targets for therapeutic
development.
INTRODUCTION
Chemical genomics employs small molecule probes to help
elucidate the relationship between genes and biological func-
tions. A forward chemical-genetic study typically begins by
perturbing a biological system with a panel of small molecules
followed by identification of the relevant targets of the compound
that generates the phenotype of interest (Stockwell, 2000).
However, small molecules can have variable specificity suchChemistry & Biology 18,that identifying the full complement of biologically relevant
protein, or other molecular targets, often presents a formidable
challenge. Traditional target identification strategies typically
employ affinity-based isolation, gel visualization, and sequenc-
ing, which is often limited and biased to a high-affinity protein-
probe association and the isolation of highly abundant proteins.
Recently, the application of stable isotope labeling by amino
acids in cell culture (SILAC)-based quantitative mass spectrom-
etry methodology using isotope-labeled cell lysates in pull-down
experiments has been shown to provide a sensitive and
unbiased means to determine cellular-binding partners of small
molecule probes (Ong et al., 2002, 2009). However, although
powerful, the use of this methodology still requires additional
strategies to reveal functionally important binding interactions,
which often remains the rate-limiting step in the ‘‘target identifi-
cation’’ challenge.
We have recently focused on the identification and develop-
ment of chemical probes and miniaturized imaging assays to
understand neuregulin-1 (Nrg1)/v-erb-a erythroblastic leukemia
viral oncogene homolog 4 (ErbB4) signaling (Kuai et al., 2010).
Nrg1 belongs to a family of four growth factors (Nrg1–4) that
each contain an epidermal growth factor (EGF)-like domain
and play a multitude of roles ranging from the regulation of cell
proliferation to synaptic plasticity. In humans the NRG1 gene
produces at least 31 isoforms in 6 types of protein (I–VI) by alter-
native splicing and proteolytic cleavage (Falls, 2003). It is
commonly believed that Nrg1 serves as a trophic factor that
signals by activating the ErbB receptor family (Bublil and Yarden,
2007), of which ErbB4 is the fourth member. Although all the
ErbB tyrosine kinase receptors are potentially activated by
Nrg1, only ErbB3 and ErbB4 have been shown to directly bind
Nrg1. ErbB2 and ErbB1 (epidermal growth factor receptor
[EGFR]) are instead activated as coreceptors (Tzahar et al.,
1994). In addition, the kinase activity of ErbB3 is impaired (Guy
et al., 1994), and ErbB4 is the only receptor that specifically891–906, July 29, 2011 ª2011 Elsevier Ltd All rights reserved 891
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AAK1 as a Regulator of Nrg1/ErbB4 Signalingbinds to Nrg1 and becomes autophosphorylated. Activation of
ErbB receptors subsequently activates many downstream
signaling pathways, including Raf-MEK-ERK and PI3K-AKT
signaling, which lead to a variety of cellular responses. In
neuronal development the Nrg1-ErbB4 signaling has been
shown to participate in crucial processes, such as neuronal
migration, axon guidance, and synapse formation (Mei and
Xiong, 2008). In mature neurons, Nrg1-ErbB4 signaling is also
implicated in synaptic plasticity and neuronal survival (Mei and
Xiong, 2008). In both cases we lack a full understanding of the
molecular mechanisms through which Nrg1-ErbB4 signaling is
regulated and how alterations of this signaling impacts cellular
physiology.
To identify small moleculemodulators of Nrg1-ErbB4 signaling
that would enable a better understanding of the underlying
molecular mechanisms, we previously established an image-
based, live cell, high throughput screening system utilizing
a PC12 cell line stably expressing human ErbB4 along with green
fluorescent protein (GFP) for ease of visualization (Kuai et al.,
2010). Native PC12 cells express the receptor for nerve growth
factor (NGF), TrkA, but do not express ErbB4. By expressing
exogenous ErbB4, the PC12-ErbB4-GFP cells are able to
respond to Nrg1 to form neurites that are morphologically very
similar to those induced by NGF. We found that several quantifi-
able features, including the average neurite length, were sensi-
tive to varying Nrg1 and NGF concentration and were suitable
surrogates of Nrg1 or NGF signaling, providing an opportunity
to find specific modulators of each neurotrophic factor. As
described in Kuai et al. (2010), a screen of bioactive compounds
using the PC12-ErbB4-GFP neurite outgrowth phenotype, we
discovered that the indolocarbazole, K252c, potentiated neurito-
genesis induced by Nrg1 but had little, if any, inhibitory effect (at
10 mM) on NGF signaling. Follow-up studies found that the fura-
nose-containing K252c analog K252a (1), a natural product orig-
inally purified from Nocardiopsis species (Kase et al., 1986),
potentiated Nrg1-induced neuritogenesis with a much higher
potency than K252c (EC50 50 nM). K252a (1) was originally
described as a potent protein kinase C (PKC) inhibitor (Kase
et al., 1986), and like many other indolocarbazoles was later
recognized as a more general kinase inhibitor with variable
selectivity (Ruegg and Burgess, 1989). Subsequently, K252a
(1) was found to potently inhibit Trk family members (Tapley
et al., 1992), PDGF receptor (Nye et al., 1992) and HGF receptor
Met (Morotti et al., 2002) signaling. Consistent with being a Trk
inhibitor, K252a (1) inhibits neuronal differentiation induced by
NGF and brain-derived neurotrophic factor (BDNF). Intriguingly,
besides blocking NGF- and BDNF-mediated signaling, K252a (1)
has also been shown to have potent neurotrophic effects in
various systems (Borasio, 1990; Glicksman et al., 1993, 1995;
Maroney et al., 1995; Roux et al., 2002). For example, K252a
(1) has been shown to enhance neurite outgrowth in human
SH-SY5Y neuroblastoma cells (Maroney et al., 1995), and in
primary neuronal cultures it was found to selectively potentiate
the neurotrophic effects of NT-3 (Knusel and Hefti, 1992; Pollack
et al., 1999). In addition, K252a (1) has also been shown to
enhance survival of dorsal root and ciliary ganglion, striatal,
and forebrain primary neuron cultures (Borasio, 1990; Glicksman
et al., 1993, 1995; Kaneko et al., 1997). However, despite the
potential therapeutic relevance of these findings, the target(s)892 Chemistry & Biology 18, 891–906, July 29, 2011 ª2011 Elsevier Lresponsible for these neurotrophic and neuroprotective proper-
ties of K252a (1), and the relationship of these processes to
each other, has remained enigmatic. Thus, to address the
target identification challenge for this important class of natural
products, we sought to apply an integrative chemical genomic
approach combining the use of synthetic active and inactive
K252a (1)-based affinity reagents in SILAC-mediated quantita-
tive proteomic profiling along with RNA interference (RNAi)-
based loss-of-function screen to subsequently validate candi-
date target proteins (Ong et al., 2009; Wang et al., 2008).
RESULTS
K252a (1) Potentiates Nrg1 but Inhibits NGF-Induced
Neuritogenesis in PC12 Cells
As first described in our high throughput cell-based screening
studies (Kuai et al., 2010), K252a (1) potentiates Nrg1-induced
neuritogenesis in PC12 cells expressing human ErbB4 within
the same dose range (1–100 nM) that inhibits NGF-induced
neuritogenesis in the same cell line, whereas K252a (1) alone
does not cause neurite outgrowth (Figures 1A and 1B). Consis-
tent with previous findings (Boulton et al., 1991; Harada et al.,
2001), 50 nM K252a (1) effectively inhibited NGF-induced
ERK1/2 phosphorylation. However, K252a (1) did not change
the autophosphorylation of ErbB4 or the downstream phosphor-
ylation of ERK1/2 induced by Nrg1 (Figure 1C). These results
suggest that the effect of K252a (1) on Nrg1-induced neurite
outgrowth differs mechanistically from its previously described
inhibitory effect on NGF/TrkA signaling.
The Structure-Activity Relationship (SAR) of K252a (1)
To identify cellular targets of K252a (1) mediating the potentiation
of Nrg1-driven neuritogenesis, we first explored the SAR of
K252a (1) in our Nrg1-ErbB4 signaling model. A small compound
library containing 22 K252a (1) analogs modified at various sites
was assembled to test their effectiveness in modulating Nrg1-
andNGF-induced neuritogenesis (Figure 2A; see Figure S1 avail-
able online). We found that all compounds with modifications at
the carbazole, indole ring, and lactam moieties were unable to
potentiate neurite outgrowth induced by Nrg1 or inhibit NGF-
induced neuritogenesis, consistent with a predicted binding
orientation of K252a (1) to a kinase pocket (Schiering et al.,
2003). Notably, compound 2 (K252a-Me), compound 7, and
compound 9 modified at the C20 position of the furanose sugar
moiety also lost their activity. On the other hand, at least two of
the compounds, compounds 5 (K252a-OH) and compound 8,
modified at the C30 position retained their ability to potentiated
Nrg1-induced neuritogenesis.
To further explore the SAR of K252a (1), based on the finding
that three analogs of K252a (1) modified at the C20 position had
diminished activities, whereas a b-hydroxy amide in the C30 posi-
tion retained its activity, we hypothesized that the C20 position is
critical for activity, whereas the C30 position would tolerate addi-
tional functional groups. To test this hypothesis, we prepared
a hybrid molecule containing both a C30-hydroxy amide and
C20-methyl (Figure 2B, compound 23, K252a-Me-OH). As pre-
dicted, this molecule did not potentiate Nrg1-induced neurite
outgrowth (Figure 2C). Interestingly, compound 2, compound
5, and compound 23 still inhibit NGF-induced neurite outgrowthtd All rights reserved
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Figure 1. K252a (1) Potentiates Nrg1-
Induced Neurite Outgrowth
(A) PC12-ErbB4-GFP cells were left untreated or
treated with K252a (1) (50 nM) for 30 min, followed
by 20 ng/ml of Nrg1 or NGF. Images were taken
after 2 days.
(B) PC12-ErbB4-GFP cells were treated with
K252a (1) at various concentrations as indicated
for 30 min, followed by treatment with 20 ng/ml of
Nrg1 (closed circles) or NGF (open circles). The
mean neurite outgrowth per cell was measured
after 2 day incubation. Error bars represent SEM
(n = 4).
(C) PC12-ErbB4-GFP cells were left untreated or
pretreated with DMSO or K252a (1) (50 nM) for
30 min, followed by 20 ng/ml of NGF or Nrg1, and
lysed after 5min. The levels of phospho-ErbB4 and
pERK1/2 were detected by western blotting with
specific antibodies. The blot was stripped and
reprobed successively with ERK1/2 antibody or
actin antibody.
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AAK1 as a Regulator of Nrg1/ErbB4 Signalingat concentrations less than 100 nM, suggesting that their ability
to inhibit TrkA was not diminished and highlighting the ability to
uncouple different signaling pathways involved in neuritogenesis
(Figure 2D). Overall, these findings reveal that not all indolocar-
bazole-containing compounds are able to potentiate Nrg1-
mediated neuritogenesis and suggest, given the sensitivity to
structural changes, that there exists a specific target mediating
the biologically effects of K252a (1) on neuritogenesis.
K252a-Affinity Agarose Captures Multiple Kinases
from Whole-Cell Lysate
Because the b-hydroxy amide (K252a-OH; 5) retained the ability
to potentiate Nrg1-induced neuritogenesis, we synthesized an
affinity probe utilizing the hydroxy amide for immobilization on
the solid support (see Supplemental Experimental Procedures
for more details). We reasoned that this affinity bead would
capture proteins from PC12-ErbB4-GFP lysate that were rele-
vant to the Nrg1-potentiating effects of the parent compound
K252a (1) (Figure 3A). As determined in an initial test using
silver-stained SDS-PAGE, the agarose-conjugated (AC) K252a
(AC-K252a) affinity probe captured multiple additional proteins
compared to unloaded agarose beads subjected to the sameChemistry & Biology 18, 891–906, July 29, 2011cell lysate (Figure 3B). We then compared
the binding profile of the AC-K252a
affinity capture probe to that of unloaded
beads (bead control) using SILAC-based
quantitative mass spectrometry (SILAC-
target ID). A total of 114 proteins were
found to bind preferentially AC-K252a
beads over unloaded beads with log2
ratio >1, of which 46 of these proteins
were kinases (Figure 3C). It is worth
noting that the identified kinases had
higher SILAC ratios than nonkinases,
suggesting that immobilized K252a-OH
(5) retained its ability to bind kinases
(Kolmogorov-Smirnov test, p = 4.79 3
1014). Although this result reflects the
actual binding profiles of AC-K252a versus the bead control,
the large number of proteins that bound to AC-K252a did not
provide immediate insight into biologically relevant binding
targets to explain the effects of K252a (1) on Nrg1-induced
neuritogenesis.
Differential SILAC-Target ID of K252a (1)
and K252a-Me (2)
In order to gain insight into the targets of K252a relevant to Nrg1-
induced neuritogenesis, we needed to further refine our strategy
to determine biologically relevant targets. Because K252a (1)
clearly potentiated Nrg1-driven neuritogenesis in a dose-depen-
dent manner, but other close structural analogs did not, we
speculated that only a limited number of the observed targets
were relevant to this phenotype. Therefore, we designed addi-
tional experiments to further narrow down the potential targets
taking advantage of the SAR we had observed for K252a (1)
analogs and the sensitivity of SILAC-based mass spectrometry
to accurately quantify differences in the binding profiles of small
molecule probes (Ong et al., 2002, 2009).
Because K252a-Me (2) and its ethanolamide analog (23) lost
the ability to potentiate neuritogenesis induced by Nrg1, butª2011 Elsevier Ltd All rights reserved 893
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Figure 2. The SAR of K252a (1)
(A) PC12-ErbB4-GFP cells were treated with DMSO or a panel of 21 K252a (1) analogs at 100 nM for 30 min, followed by 20 ng/ml of Nrg1 (black bars) or NGF
(white bars). Images were taken after 2 days and analyzed. The average neurite outgrowth of each treatment was normalized against DMSO.
(B–D) (B) Structures of K252a (1), K252a-Me (2), K252a-OH (5), and K252a-Me-OH (23). The structures of all other K252a analogs are shown in Figure S1. PC12-
ErbB4-GFP cells were treated with K252a (1) (closed circles), K252a-Me (open circles), K252a-OH (5) (closed squares), or K252a-Me-OH (23) (open squares) at
various concentrations as indicated for 30 min, followed by treatment with 20 ng/ml of Nrg1 (C) or NGF (D). The mean neurite outgrowth per cell was measured
after 2 day incubation. Error bars represent SEM (n = 4).
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AAK1 as a Regulator of Nrg1/ErbB4 Signalingwere still able to inhibit NGF-dependent neurite outgrowth, we
hypothesized that the additional methyl group of K252a-Me (2)
alters the target selectivity compared to K252a (1) such that
a relevant target would not bind to an K252a-Me (2)-based
affinity capture probe. Therefore, we prepared another affinity
capture probe, AC-K252a-Me, using K252a-Me-OH (23), to
serve as an inactive analog for comparison to the AC-K252a
probe using the SILAC-target ID method. Globally, the SILAC
ratios of proteins quantified in both AC-K252a and AC-K252a-
Me experiments were relatively consistent, suggesting that the
binding profiles of these two beads were overall quite similar
(Figures 3D and 3E).
The protein-binding profiles of AC-K252a and AC-K252a-Me
affinity capture probes were then directly compared with three
independent experiments. The first two experiments comparing894 Chemistry & Biology 18, 891–906, July 29, 2011 ª2011 Elsevier LAC-K252a (‘‘active’’) versus AC-K252a-Me (‘‘inactive’’) were per-
formed as technical replicates with bait swapping, an approach
where a respective SILAC lysate-bead combination from one
replicate was ‘‘swapped’’ in the second replicate. In doing so,
SILAC ratios for bona fide hits are expected to flip in the
two experiments, whereas false positives are not, providing
a very powerful filter for quantifying false-positive interactions.
Additionally, beads from the two ‘‘forward’’ and ‘‘reverse’’ exper-
iments were washed with our standard lysis buffer (Ong et al.,
2009), but in the third experiment we used a lysis buffer with
0.2% SDS for an additional higher stringency wash to strip off
weaker protein binders. We also included two different bead
control experimental designs using the same set of lysates: (1)
‘‘inactive’’ versus ‘‘active;’’ and (2) ‘‘active’’ versus bead controls,
which both provided distinct information. The former directlytd All rights reserved
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Figure 3. Kinases Captured by a K252a (1)-Based Affinity Capture Probe
(A) Scheme for generating agarose-conjugated K252a (1)-based (AC-K252a) and K252a-Me (2)-based (AC-K252a-Me) affinity capture probes.
(B) PC12-ErbB4-GFP cells were lysed and captured by unloaded agarose and AC-K252a. Eluted proteins were analyzed by SDS-PAGE with silver staining.
Arrowheads represent the areas with visible differences.
(C) Stacked histogram of binding ratios of AC-K252a versus bead control (BC) detected by SILAC. Inset shows rank order of detected proteins. Kinases are
represented in red. Nonkinases are represented in black.
(D) Stacked histogram of binding ratios of AC-K252a-Me versus BC detected by SILAC. Inset illustrates rank order of detected proteins. Kinases are represented
in red. Nonkinases are represented in black.
(E) X axis, ratios of AC-K252a versus BC; y axis, ratio of AC-K252a-Me versus BC. Only genes that were present in both data sets were plotted and subjected to
linear regression. The resulting function and correlation coefficient are included, showing globally the similarity between the two different affinity matrices.
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Figure 4. Differential Affinity Enrichment with
AC-K252a versus AC-K252a-Me Affinity Capture
Probes
(A) Summary of identified candidate targets of K252a (1)
based on five independent SILAC pull-down experiments.
Our selection criteria (see main text) identified candidates
with ratios indicating differential selectivity for active
K252a (1) over K252a-Me (2) in direct comparisons with LS
and HS wash conditions and from molecule versus bead
control (BC) experiments. FWD, forward; REV, reverse.
(B) PC12-ErbB4-GFP cell lysate was incubated with
control agarose, AC-K252a, and AC-K252a-Me agarose
beads. Eluted proteins were analyzed by western blotting
with specific antibodies for PKCa, ERK1/2, GSK3b, and
PKC3.
See also Table S1.
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AAK1 as a Regulator of Nrg1/ErbB4 Signalingcompared a protein’s relative binding to the inactive and active
K252a (1) analogs, whereas the latter enabled the determination
of a protein binding to the small molecule itself relative to beads
alone (i.e., bead controls). For our analyses we primarily used
the SILAC ratios in bead control experiments to categorize
proteins broadly as ‘‘K252a-binders’’ or ‘‘K252a-Me binders.’’
Proteins identified with differential ratios in a subset of ‘‘inactive’’
versus ‘‘active’’ experiments may be false positives, and the
bead control experiments can help filter these out based on
the requirement that a relevant target also show significant
enrichment by the affinity capture probe. Candidate targets
were ultimately selected based on the following criteria: (1) log2
ratio of ‘‘active’’ versus ‘‘inactive’’ greater than 1.0; (2) log2 ratio
of ‘‘active’’ versus bead control greater than 1.0; and (3) log2 ratio
of ‘‘active’’ versus bead control greater than log2 ratio of ‘‘inac-
tive’’ versus bead control by 1.0 (log2 ratios for missing values
were set at zero). With these criteria we identified 18 proteins
including 13 kinases as putative targets of K252a (1) for Nrg1-
induced neuritogenesis (Figure 4A; Table S1). Strikingly, at least
three functional clusters could be detected in the short list of
candidate target proteins. There were five proteins belonging to
the MAPK family, three subunits (PRKAR2A, PRKAR2B, and
PRKACB) of cAMP-dependent protein kinase A (PKA), and three896 Chemistry & Biology 18, 891–906, July 29, 2011 ª2011 Elsevier Ltd All rights resemembers (AAK1, AP2M1, and AP2B1) of the cla-
thrin-adaptor protein complex (Conner et al.,
2003).
To begin to validate the SILAC-target ID
results, we first examined the binding profiles
of several identified kinases to the three beads
by western blotting in whole-cell lysate pull-
downs. As found in the SILAC-target ID data,
PKCa, ERK1, and ERK2 were captured by AC-
K252a only and substantially less by AC-
K252a-Me. On the other hand, PKC3, which
was not identified as enriched in either SILAC
experiments, showed equal binding to all three
agarose beads (Figure 4B). We also found by
western blot that GSK3b (SILAC active/inactive
log2 ratio 0.058) was captured equally by both
AC-K252a and AC-K252a-Me. Thus, these
results validated the initial SILAC-target ID
experiments andmotivated the use of functionalassays to explore the biological relevance of the interactions of
proteins with K252a (1).
Functional Genomic Screen of SILAC-Target ID
Candidates Using RNAi
To further clarify the relevant target of K252a (1), we next turned
to a functional genomic screening approach using lentiviral small
hairpin RNAs (shRNAs) to knock down candidate genes identi-
fied by the SILAC-target ID experiment, followed by observing
the effect of loss of function using the Nrg1-induced neuritogen-
esis imaging assay. We reasoned that if a protein identified
by the differential affinity enrichment experiment was indeed
inhibited by K252a (1), then this approach would recapitulate
the same phenotypic effect as treatment of cells with K252a (1)
and Nrg1. With a coverage of 4–5 shRNAs tested per gene, we
tested 13 of the 18 candidate targets for a total of 68 shRNAs
and identified 9 hairpins covering a total of 5 separate genes
(AAK1 [2 out of 4 shRNAs], AP2M1 [3 out of 5 shRNAs], PRKCA
[1 out of 5 shRNAs], MAP2K2 [2 out of 5 shRNAs], and MAP2K4
[1 out of 5 shRNAs]) that substantially potentiated Nrg1-induced
neurite outgrowth when silenced (Figures 5A and 5B). Because
any one shRNA may have off-target effects, to control for spec-
ificity, we applied a filter requiring that more than one shRNArved
AC
D
B Figure 5. Knocking Down of AAK1 Potenti-
ates Nrg1-Driven Neuritogenesis
(A) Silencing the candidate genes with lentiviral-
packaged shRNAs. Five genes that have at
least one corresponding shRNA hairpin that
potentiates Nrg1-induced neurite outgrowth are
shown (for complete results see Table S2). Cells
were infected by shRNA containing viruses for
2days, followedby treatment of 20ng/mlNrg1. The
average neurite length in each hairpin treatment
was analyzed and normalized to control a virus,
which contained a nontargeting shRNA and ex-
pressed RFP (error bar represents SEM; n = 2).
(B) Representative image of PC12-ErbB4-GFP
cells infectedwith control or AAK1 shRNA hairpin 4
and induced by Nrg1 for 2 days.
(C) PC12-ErbB4-GFP cells were transfected with
siRNA targeting the five genes identified in (A) or
nontargeting control siRNA (SC) (white bars), then
treated with or without 100 nM K252a, followed by
20 ng/ml Nrg1 for 2 days (black bars). Average
neurite length per cell of each treatment was
normalized to that of the control siRNA.
(D) Western blots confirming the knockdown of
each gene as indicated.
See also Figure S2.
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AAK1 as a Regulator of Nrg1/ErbB4 Signalingenhanced neurite outgrowth, leaving three candidate genes. The
strongest effect on neurite outgrowth in the presence of Nrg1
was obtained with multiple shRNAs targeting AAK1 (Figures 5A
and 5B). Notably, three out of the five shRNAs targeting
AP2M1 alsomet our criteria, although themagnitude of the effect
was less robust. This was notable because AAK1 is a member of
the ARK1/PRK1 family of serine/threonine kinases known to
phosphorylate AP2M1 (adaptor-related protein complex 2, mu
(m) 1 also known as m2), a subunit of the clathrin-adaptor complex
AP2 involved in clathrin-dependent receptor endocytosis and
receptor recycling (Conner and Schmid, 2002; Henderson and
Conner, 2007; Ricotta et al., 2002; Smythe and Ayscough, 2003).
To confirm the results of the shRNA-mediated silencing, we
subsequently retested the genes with the strongest lentiviral
shRNA phenotypes using synthetic small inhibitory RNAs
(siRNAs). Using this dual RNAi approach, and full validation of
knockdown efficiency, we were able to confirm that silencingChemistry & Biology 18, 891–906, July 29, 2011of AAK1 potentiated Nrg1-induced neuri-
togenesis (Figures 5C and 5D), but
silencing of the other four candidate
genes, AP2M1, PRKCA, MAP2K2, and
MAP2K4, did not potentiate Nrg1-
induced neuritogenesis. Acknowledging
the discrepancy between the two gene-
silencing methods, which could be due
to differences in the efficiency of knock-
down or specificity of the probes, the
agreement between the two methods on
AAK1 strongly suggests that AAK1 is
a plausible target of K252a (1) involved
in potentiating Nrg1-induced neuritogen-
esis. Consistent with this notion, there
was no effect of silencing AAK1 on neuri-togenesis in the absence of Nrg1 treatment (data not shown), nor
was there an effect of silencing AAK1 on NGF-stimulated neuri-
togenesis (Figure S2). These findings are consistent with the
observation that K252a treatment has neither an effect on the
binding of iodinated NGF nor the internalization of NGF in
PC12 cells (Koizumi et al., 1988). Finally, the potentiation effect
of K252a (1) was diminished in AAK1-silenced cells, compared
to that of scrambled control and other siRNAs (Figures 5C and
5D).
Differential Inhibition of AAK1 by K252a (1)
and K252a-Me (2)
Because the RNAi data suggested that AAK1 was a candidate
target of K252a (1) involved in Nrg1-induced neuritogenesis,
we further investigated whether AAK1 showed differential
affinity for AC-K252a and AC-K252a-Me using direct binding
experiments. We first reexamined affinity capture with theseª2011 Elsevier Ltd All rights reserved 897
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AAK1 as a Regulator of Nrg1/ErbB4 Signalingprobes from whole-cell lysates and found that AAK1 was
specifically bound by AC-K252a and, to a much lesser extent,
by AC-K252a-Me (Figure 6A). This result suggested that K252a
(1) is associated with a complex that at least contains AAK1
but does not prove direct binding. To determine if this associa-
tion was direct, we tested the affinity of both agarose beads to
purified AAK1 (D-AID), a truncated AAK1 that included the active
kinase domain with a C-terminal glutathione S-transferase (GST)
tag (Conner et al., 2003). Consistent with cell lysate results, the
D-AID AAK1-GST fusion protein was captured by AC-K252a
but to a much lesser extent by AC-K252a-Me, suggesting that
AAK1 indeed has a greater affinity toward K252a (1) than
K252a-Me (2) (Figure 6B). Furthermore, in control experiments
we found that, consistent with our SILAC experiments, purified
GSK3b bound to both affinity matrices equally (Figure 6B).
Finally, to test if this binding of K252a (1) had a functional effect
on AAK1, we determined if K252a (1) and K252a-Me (2) differen-
tially inhibited recombinant AAK1 kinase activity. Using the same
recombinant D-AID AAK1-GST fusion protein as for the pull-
down experiments, we developed an in vitro AAK1 kinase assay
using a synthetic peptide substrate consisting of a sequence
flanking the known AAK1 phosphorylation site (Thr156) on
AP2M1. As shown in Figure 6C, K252a (1) potently inhibited
AAK1’s kinase activity with an IC50 <10 nM, which was three
orders of magnitude more potent than the inhibition of AAK1
by K252a-Me (2). By contrast, both analogs inhibited recombi-
nant GSK3b kinase activity with only a 2-fold difference in
efficiency (Figure 6D), highlighting the remarkable ability of the
SILAC-target ID experiment to have revealed differential binding
of AAK1 to K252a (1) over K252a-Me (2), even in the context of
many competing protein-small molecule interactions in a com-
plex cell lysate.
Computational Studies of Binding of K252a (1)
and K252a-Me (2) to AAK1
The integrative SILAC-target ID and functional genomic
approach we employed here identified a group of kinases that
can be discriminated by K252a (1) and K252a-Me (2). Although
it has been established that indolocarbazoles like K252a (1)
occupy the hydrophobic adenine-binding pocket, with the sugar
moiety mimicking the hydrogen-bonding pattern of adenine in
the ATP-binding site (Sanchez et al., 2006), the subtle nature
and location of the 20 methyl modification of K252a-Me (2)
prompted us to try to gain insight into the nature of how this
modification diminishes the affinity for kinase targets using
computational modeling.
Using the thermodynamic integration theoretical free energy
(TI) approach (Pearlman, 1998), the relative binding free energies
for the unmethylated and C20 methylated forms of K252a (1)
were determined. The TI approach, which combines molecular
dynamics with equations of elementary statistical mechanics,
has been widely studied, and has been demonstrated capable
of determining quantitatively reliable relative binding free energy
estimates (see Supplemental Experimental Procedures for more
details).
Because there is no crystallographic structure for AAK1,
a homology model was created using the MOE package (2007),
starting with crystal structure of the human serine-threonine
kinase 16 (2BUJ) (Debreczeni et al., 2005), with which there is898 Chemistry & Biology 18, 891–906, July 29, 2011 ª2011 Elsevier L25.8% total sequence homology. Initial placement of the K252a
(1) ligand in our homology model was determined by superposi-
tion of the AAK1 homology model with the crystal structure of
the tyrosine kinase domain of c-Met bound by K252a (1r0p)
(Schiering et al., 2003) (Figure S3). The individual calculated
free energies from this model are presented in Supplemental
Experimental Procedures. From these values a net DDG =
DGT2DGT1 = DGE2DGE1 = 2.69 ± 0.46 kcal/mol was deter-
mined. In other words, adding a C20 methyl group to K252a is
2.69 kcal/mol more unfavorable in the AAK1-bound state than
in the free state, and so adding the C20 methyl group disfavors
binding by this degree. Converted to a binding constant,
2.69 kcal/mol translates to a factor of 94 or a little less than two
orders of magnitude of binding affinity. From further breakdown
of the thermodynamic cycle in these experiments, it appears
that nearly all of the differences arise from nonbonded (nonpolar)
interactions, and not from, for example, solvent rearrangement.
This suggests that the difference in preference of binding to
AAK1 to K252a (1) arises primarily from the fact that placing
a methyl group at the C20 position of K252a-Me (2) is sterically
unfavorable and requires the adoption of a higher energy set of
configuration states for either the ligand, the AAK1, or both (Fig-
ure S3). In light of the good agreement between the binding
energydetermined in these computational studies and the exper-
imentally observed differences in binding affinity of one to two
orders of magnitude, the sterically less favorable interactions,
of K252a-Me (2), provide a potential explanation for the observed
difference in inhibitory potency of K252a (1) and K252a-Me (2)
toward AAK1 (Figure 6E).
K252a (1), but Not K252a-Me (2), Increases ErbB4 Levels
in PC12-ErbB4-GFP Cells
Given the suggested role of AAK1 in clathrin-dependent receptor
endocytosis (Conner and Schmid, 2002), and our demonstration
for the first time of the ability of K252a (1) to inhibit the phosphor-
ylation of Thr156 on AP2M1 (Figure 6C), a site known to be
critically involved in regulating endocytic trafficking (Olusanya
et al., 2001; Ricotta et al., 2002), we speculated that the neuro-
trophic effects of K252a (1) were related to its effect on some
aspect of ErbB4 receptor trafficking. To test this hypothesis,
we first examined total ErbB4 levels in PC12 cells treated with
50 nM K252a (1) or 50 nM K252a-Me (2) using western
blotting. As shown in Figure 7A, treatment with K252a (1) dramat-
ically increased the level of ErbB4, whereas K252a-Me (2) and
DMSO both had no effect. Consistently, AAK1 knockdown by
siRNA treatment also led to an increased level of total ErbB4 in
cells (Figure 7B). This effect on ErbB4 was specific to AAK1
silencing because no effect was observed with scrambled siRNA
or with a siRNA pool targeting PKCa (Figure 7B). Taken together,
these results provide an additional level of similarity of the effect
of K252a (1) treatment and AAK1 loss of function.
To gain additional insight into the basis for accumulation
of ErbB4 levels, we then performed immunocytochemistry to
localize ErbB4 in cells treated with K252a (1) or with siRNAs
targeting AAK1. Interestingly, the intracytoplasmic localization
of ErbB4 was greatly reduced in cells treated with K252a (1)
and in AAK1 knockdown cells, but not in cells treated
with a scrambled control siRNA or K252a-Me (2) (Figure 7C).
These results revealed that the accumulated ErbB4 in bothtd All rights reserved
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Figure 6. AAK1 Binds Directly and Specifically to K252a (1)
(A) Western blots of proteins from PC12-ErbB4-GFP cells bound by AC-K252a or AC-K252a-Me. Western blots were probed with AAK1 antisera and then
stripped and reprobed with ERK1/2 antisera. AAK1 and ERK1/2 were marked with arrowheads, and nonspecific bands were marked with asterisks.
(B) GST-tagged AAK1 (D-AID) was affinity captured by unloaded agarose, AC-K252a, and AC-K252a-Me, and bound protein was analyzed by silver staining
(upper panel) and western blotting (lower panel). A nonspecific band shown in the silver-stained gel is marked with an asterisk, and AAK1-GST was marked with
an arrowhead in the western bot.
(C) Kinase activity of GST-tagged AAK1 (D-AID) was measured with K252a (1) (closed circles) or K252a-Me (2) (open circles) at the concentrations indicated. IC50
for AAK1 is indicated in the legend.
(D) Kinase activity of GST-taggedGSK3bwasmeasuredwith K252a (1) (closed circles) or K252a-Me (2) (open circles) at the concentrations indicated. The IC50 for
GSK3b is indicated in the legend.
(E) AAK1 homology model comparing the binding of K252a (1) and K252a-Me (2).
See also Figure S3.
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Figure 7. K252a (1) Treatment and AAK1
Knockdown Both Cause Accumulation of
ErbB4 and Diminish Cytosolic Localization
of ErbB4
(A) PC12-ErbB4-GFP cells were untreated or
treated with 50 nM K252a (1) or 50 nM K252a-Me (2)
for 12 hr, and ErbB4 was detected by western
blotting with an anti-ErbB4 antibody.
(B) PC12-ErbB4-GFP cells were transfected with
AAK1, PKCa, and scrambled siRNA for 2 days, and
ErbB4, AAK1, PKCa, and actin were detected by
western blotting.
(C) PC12-GFP control cells were left untreated (a)
and PC12-ErbB4-GFP cells were untreated (b), or
treated with scrambled (SC) siRNA (c), 50 nM K252a
(1) (d), 50 nM K252a-Me (2) (e), or transfected with
AAK1 siRNA (f). The cells were then fixed and per-
meabilized, followed by immunocytochemistry with
an antibody that recognizes the extracellular domain
of ErbB4. Images were taken at 203 magnification.
Note the ErbB4 staining indicated by arrows in
untreated, SC siRNA, and K252a-Me (2)-treated
cells and the decreased ErbB4 levels in AAK1-
siRNA-transfected and K252a (1)-treated cells.
See also Figure S4.
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AAK1 as a Regulator of Nrg1/ErbB4 SignalingK252a (1)-treated and AAK1 knockdown cells was mainly
located in close proximity or within the outer plasma membrane.
Again, the correspondence between the K252a (1) and siRNA
cellular ErbB4 localization phenotypes further supports the
conclusion of the relevance of AAK1 as a target involved in
potentiation of Nrg1-induced neuritogenesis.
Finally, to further investigate the possible mechanism through
which K252a-mediated inhibition of AAK1 potentiates Nrg1-
induced signaling and neuritogenesis, we sought to determine
if K252a (1) treatment was capable of altering ErbB4 endocy-
tosis. Previously, fluorescently labeled Nrg1 has been shown
to be coendocytosed with ErbB4 in HEK293 cells and in rat
hippocampal neurons (Liu et al., 2007; Yang et al., 2005). Consis-
tent with these findings, after incubation with Alexa 594-Nrg1 at
37C for 30min, PC12-ErbB4-GFP cells, but not PC12-GFP cells
that lack the ErbB4 receptor, exhibited numerous fluorescent
punctae typical for endocytic particles (Liu et al., 2007; Yang900 Chemistry & Biology 18, 891–906, July 29, 2011 ª2011 Elsevier Ltd All rights reservedet al., 2005) (Figure S4). This punctate
labeling of PC12-ErbB4-GFP cells could
be blocked by treatment with excess unla-
beled Nrg1, but not EGF (data not shown).
To determine if K252a (1) affected the
endocytosis of Alexa 594-Nrg1, cells
were pretreated for 12 hr with K252a (1),
followed by a 30 min treatment at 37C
with Alexa 594-Nrg1. Following fixation
and costaining for ErbB4, cells were
imaged using confocal microscopy. As
shown in Figure S4, K252a (1) pretreated
cells showed elevated total protein and
membrane levels of ErbB4 and appeared
to exhibit enhanced intracellular, Alexa
594-Nrg1 punctae that colocalized with
ErbB4. These results suggest that, at leastto the limits of our detection methods, the stimulation of Nrg1-
mediated neuritogenesis through K252a-mediated AAK1 or
siRNA silencing of AAK1 does not involve blocking Nrg1-induced
ErbB4 endocytosis.
DISCUSSION
In the present study we characterized the ability of K252a (1), an
extensively used indolocarbazole natural product, to potentiate
Nrg1-induced neuritogenesis. Neuritogenesis, the earliest stage
of neural cell differentiation, involves the formation of neurites
that play an important role in neural migration and patterning.
Despite the importance of neuritogenesis for proper neural
circuit formation, our understanding of the underlying molecular
mechanisms and our ability to modulate them remain limited.
Gaining an understanding of themolecular machinery andmech-
anisms that generate and remodel neural circuits is necessary
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AAK1 as a Regulator of Nrg1/ErbB4 Signalingfor the development of small molecule probes that can modulate
these processes for potential therapeutic benefit.
By exploring the chemical space around K252a (1) (Figure 2A;
Figure S1), we found that the C30 position of the furanose
moiety could accommodate certain modifications while main-
taining cellular activity. In particular the b-hydroxy amide analog
(5) allowed us to immobilize K252a (1) to generate an affinity
capture probe (AC-K252a) to try to enrich for protein binders.
Use of the AC-K252a probe was found to enrich for at least 46
kinases from cellular lysates, as detected by SILAC-based quan-
titative mass spectrometry, consistent with the expectation that
indolocarbazoles such as K252a (1) interact with many kinases.
Because the C20 position of the furanosemoiety of K252a (1) was
sensitive to modification with even the addition of methyl group
at this site being capable of causing a loss of activity with respect
to Nrg1-induced neuritogenesis, this prompted us to use an AC-
K252a-Me affinity capture probe to eliminate irrelevant targets
based on the hypothesis that K252a-Me (2) did not inhibit the
relevant targets. With quantitative mass spectrometry enabled
through the use of SILAC, we further narrowed down our candi-
date list to 18 proteins, including 13 kinases, which preferentially
bind to K252a (1) over K252a-Me (2). This demonstrates the
effectiveness of using a structurally similar, but biologically inac-
tive, analog of the small molecule of interest to dissect out irrel-
evant targets when using the SILAC-target ID methodology. In
addition the surface difference between immobilized active
compound and inactive compound is presumably more similar
than that of unloaded agarose beads, therefore reducing false-
positive identification. Based on these reasons, the combination
of SILAC-based quantitative mass spectrometry with affinity
enrichment with active and inactive compounds provides a
useful target identification strategy. Alternatively, competition
with soluble competitor is another strategy that has proven
successful for target identification using the SILAC approach
(Ong et al., 2009), particularly if the quantity and solubility of
competitor are not a concern and an inactive structural analog
is not known.
During the target validation process, we used a lentiviral-medi-
ated RNAi loss-of-function screen to validate candidate target
proteins and found that AAK1 reproducibly potentiated Nrg1-
driven neuritogenesis when knocked down with both lentiviral
shRNAs and siRNAs. Our follow-up characterization confirmed
the SILAC affinity purification studies through the demonstration
of a direct and functional interaction of AAK1 with K252a (1) (Fig-
ure 6A). Furthermore, the relevance of AAK1 as a target of K252a
(1) is also supported by our computational modeling of the
interaction of K252a (1) and K252a-Me (2) with a homology
model of AAK1, which revealed subtle but notable differences
in the binding energy and mode between the two small mole-
cules and the ATP-binding site of AAK1.
The sensitivity and specificity of the SILAC-target ID assay are
afforded by the use of mild buffer conditions that may allow the
observation of weaker small molecule-protein interactions and
multiprotein complexes, whereas quantitative mass spectrom-
etry-based abundance measurements determine the specificity
of proteins bound to affinity baits (Ong et al., 2009). In agreement
with these attributes, and providing further support that AAK1 is
a cellular target of K252a (1) involved in mediating its neurotro-
phic effect, the SILAC-target ID experiments also yieldedChemistry & Biology 18,AP2M1 and AP2B1, two known binding partners of AAK1, as
binders to the Ac-K252a (1) but not the AC-K252a-Me (2) affinity
capture probes.
AAK1 belongs to the ARK/PRK family of serine/threonine
kinases that share homologies in their kinase domain but exhibit
a diverse range of other functional domains. In yeast, ARK and
PRK have been shown to function in endocytosis by regulating
actin dynamics. However, inmammalian cells, to our knowledge,
there is currently no evidence to suggest that AAK1 influences
actin dynamics. AAK1 kinase activity is robustly stimulated by
clathrin, suggesting a key role for AAK1 in regulating clathrin-
mediated endocytosis (Conner et al., 2003), although it remains
unclear if the kinase activity of AAK1 is required for the uptake of
any particular receptor, which is an active area of investigation.
Given our isolation of AAK1 and AP2 adaptor complex-associ-
ated proteins with our K252a-based affinity probes, and the
observation of the elevated total levels of ErbB4 and its redistri-
bution toward cellular membranes upon treatment with K252a (1)
and RNAi-mediated gene silencing of AAK1, it is tempting to
speculate that the loss of function of AAK1 leads to an ErbB4
internalization defect due to altered clathrin-mediated endocy-
tosis (Conner and Schmid, 2002; Ricotta et al., 2002; Smythe
and Ayscough, 2003). Although the mechanism of internalization
of ErbB4 is poorly understood (Baulida et al., 1996; Sorkin and
Goh, 2008), several recent studies have demonstrated that
endocytosis of ErbB4 does occur in various cellular systems,
and regulation of this process may be a critical component of
the dynamic regulation of Nrg1-ErbB4 signaling, particularly in
neurons (Liu et al., 2007; Longart et al., 2007; Sundvall et al.,
2008).
However, besides playing a key role in regulating AP2 recruit-
ment to endocytic cargo through phosphorylation of m2 (Ricotta
et al., 2002), AAK1 has been shown to function at multiple steps
in receptor transport including receptor recycling from the early
endosome and pathways involved in protein degradation
(Henderson and Conner, 2007). In support of the interpretation
that the effect of K252a-mediated AAK1 inhibition does not
block Nrg1-stimulated ErbB4 endocytosis, previous studies
have shown that the inhibition of ErbB4 endocytosis attenuated
Nrg1-induced activation of ERK1/2 (Liu et al., 2007), whereas
we did not observe such attenuation with K252a (1) treatment
(Figure 1). Thus, our data suggest that the observed accumula-
tion of ErbB4 on the surface of the cells and the observed
increase in total ErbB4 protein levels are ultimately more likely
the result of blocking a critical step in ErbB4 trafficking. One
possibility for this block is that K252a-mediated AAK1 inhibition
causes alteration in endosomal sorting of the ErbB4 receptor,
possibly thereby directing ErbB4 back to the plasmamembrane.
Alternatively, AAK1 inhibition may result in a failure to direct
transport of ErbB4 toward degradation in the lysosome. At
present, without more detailed pulse-chase labeling studies,
higher-resolution imaging, and investigation of the kinetics of
ErbB4 trafficking, we cannot distinguish between these possibil-
ities and cannot rigorously rule out a role for K252a-mediated
inhibition of AAK1 in blocking ErbB4 endocytosis. Such studies
would also benefit from the identification of selective AAK1
probes, which remains an area for future studies.
Similar to other members of the EGFR(/ErbB) family of
receptor tyrosine kinases, signal transduction of the ErbB4891–906, July 29, 2011 ª2011 Elsevier Ltd All rights reserved 901
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phorylation of cytoplasmic tyrosine residues to afford coupling to
downstream singling molecules. Therefore, if ErbB4’s kinase
activity was modulated by AAK1 inhibition, this would be
expected to result in a change in the phosphorylation state of
ErbB4. However, we see no evidence for an increase in the tyro-
sine phosphorylation levels of ErbB4 upon treatment with K252a
alone (Figure 1C), suggesting that AAK1 inhibition does not itself
directly affect ErbB4 kinase activity. Furthermore, if ErbB4’s
kinase activity is modulated by AAK1, K252a treatment alone
should have downstream functional consequences of ErbB4
signaling, including ERK1/2 phosphorylation and neuritogenesis.
As shown, neither the treatment of cells with K252a alone (Fig-
ure 1) nor silencing of AAK1 with siRNAs (Figure 5) had an effect
on neuritogenesis or downstream ERK1/2 activation in the
absence of Nrg1 treatment, suggesting again that AAK1 inhibi-
tion does itself not affect ErbB4 kinase activity.
Indolocarbazoles, such as K252a (1), belong to a family of
natural products that have been extensively studied in the past
decade, owing in part due to their wide-ranging biological
activities. With their planar structure and indole rings, they
have been shown through crystallographic studies to bind in
the ATP-binding pocket in a competitive manner with ATP. Given
the similarity of ATP-binding pockets among kinases, many
indolocarbazole inhibitors possess high potency but low selec-
tivity among the members of the kinome. For example, stauro-
sporine, the first indolocarbazole isolated in 1977, was shown
to have affinity with most of the kinases in human kinome (Fabian
et al., 2005; Karaman et al., 2008). After first being demonstrated
to be an inhibitor in the nanomolar range of NGF-induced
biochemical effects and neurite outgrowth in PC12 cells (Cho
et al., 1989; Hashimoto, 1988; Koizumi et al., 1988; Lazarovici
et al., 1989; Miyasaka et al., 1990; Smith et al., 1989), Berg et al.
(1992) went on to demonstrate that K252a directly inhibits NGF-
induced Trk receptor tyrosine phosphorylation in cells and
kinase activity in vitro in a dose-dependent manner. These early
studies also suggested that K252a may have one or more addi-
tional cellular targets involved in the process of signal transduc-
tion (Berg et al., 1992). It was also recognized that improved
selectivity can be obtained by modifying the mode of ligand
interaction. A wide variety of structures within the indolocarba-
zole family have been found to have selectivity for particular
kinases, such as PKC isozymes (Zhang et al., 2005), CDKs
(Al-awar et al., 2004), GSK3b (Kuo et al., 2003), VEGF-R2
tyrosine kinase (Gingrich et al., 2003), andmixed lineage kinases
(MLKs) (Murakata et al., 2002). A number of indolocarbazoles
have been or are still in clinical development for disease indica-
tions in the area of oncology and neurodegeneration. In the
context of developing agents to treat neurodegenerative
disorders, previous studies have evaluated the neuroprotective
effects of a series of 3,9-disubstitued K252a (1) derivatives, as
measured by the in vitro enhancement of choline acetyltransfer-
ase activity in primary rat spinal cord and forebrain cultures
(Kaneko et al., 1997). These compounds, while showing in-
creased neurotrophic activity over K252a (1), showed decreased
ability to inhibit Trk kinase activity. One of these K252a (1) deriv-
atives known as CEP1347 (compound 10) has been reported to
have neuroprotective effects through inhibiting MLK family
members (Roux et al., 2002). However, CEP1347 (compound902 Chemistry & Biology 18, 891–906, July 29, 2011 ª2011 Elsevier L10) did not potentiate Nrg1-induced neurite outgrowth in our
PC12-ErbB4-GFP cellular assays. This result suggests that the
potentiation by K252a (1) of Nrg1-induced neuritogenesis is
distinct from the neuroprotective features reported previously
for 3,9-disubstitued K252a (1) derivatives. This conclusion is
further supported by the fact that we found no support for
MLKs as being relevant targets of K252a (1) in PC12 cells from
our SILAC-based target identification studies.
In now classic experiments in the field of signal transduction
(Greene and Tischler, 1976; Heasley and Johnson, 1992; Kaplan
et al., 1991a, 1991b; Traverse et al., 1992), sustained activation
of ERK1/2 was shown to occur in response to NGF, whereas
EGF treatment, which induces a mitogenic response leading
to cell proliferation, led to a short-lived ERK1/2 activation. These
observations provided a model system for the dissection of
how activation of certain receptors that couple to the same
effector signaling molecules can lead to differential biological
outcomes.
In our study the same small molecule probe, K252a (1), leads
to differential biological outcomes in a manner dependent upon
the nature of the signal transduction cascade activated by
different neurotrophic factors. With NGF treatment, because
K252a (1) has a direct inhibitory effect on the tyrosine kinase
activity of the Trk receptor that blocks the sustained activation
of ERK1/2 that normally occurs upon NGF treatment (Berg
et al., 1992), the observed dose-dependent inhibition of neurito-
genesis and correlation we observe in Figure 1B between loss of
ERK1/2 phosphorylation and lack of increased neurite length are
expected. In contrast, with Nrg1 treatment, which as shown in
Figure 1C, also causes activation of ERK1/2, K252a (1) treatment
does not inhibit ERK1/2 activation but insteadmaintains the level
of ERK1/2 activation, leading to an increase in neurite length
(Figure 1B). These results demonstrating distinct effects of
K252a (1) on different signaling pathways are consistent with
the earlier observation that EGF and bFGF-stimulated protein
tyrosine phosphorylation in PC12 cells was unaffected by
K252a (1) treatment (Berg et al., 1992).
In the case of Nrg1/ErbB4 signaling, because both K252a (1)
treatment and AAK1 siRNA-mediated gene silencing led to
increased levels of ErbB4 (Figures 7A and 7B) that can be
observed on the cell membrane (Figure 7C), it is plausible that
K252a (1)-mediated inhibition of AAK1 leads to a sustained
activation by ErbB4 of downstream signaling, including the
activation of ERK1/2, leading to enhanced Nrg1-mediated
neuritogenesis. This model for the biological effects of K252a
(1) on Nrg1-dependent neurotrophic factor signaling highlights
the fact that, despite different neurotrophic factors having
shared signal transduction pathways downstream from their
receptors, it is possible to identify small molecule probes that
can target a unique aspect of the underling molecular mecha-
nisms. Identification of these targets, such as AAK1 for Nrg1/
ErbB4 signaling, may lead to novel types of therapeutic agents
for a variety of CNS disorders in which there is dysfunction of
neurotrophic factor signaling.
SIGNIFICANCE
The discovery of low-molecular weight small molecules with
neurotrophic modulating activity represents a valuabletd All rights reserved
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signaling mechanisms to human disease. The blood-brain
barrier impermeability and overall pharmacokinetic charac-
teristics of most polypeptide-based neurotrophic factors
limit their ability tobeadministeredsystemically for the treat-
ment of many CNS disorders. In the case of schizophrenia
(OMIM 181500), a highly heritable and devastating neuropsy-
chiatric disorder, although there is still conflicting genetic
evidence, several genetic, transgenic mouse, and post-
mortem human brain studies have suggested Nrg1 and
ErbB4 as putative susceptibility genes (Mei and Xiong,
2008; Buonanno, 2010). Given the observations that Nrg1
regulates excitatory pyramidal neurons in the prefrontal
cortex via presynaptic ErbB4 receptors on parvalbumin-
positive GABAergic interneurons (Woo et al., 2007), as well
as recent findings that have shown the ablation of ErbB4 in
parvalbumin-positive interneurons inmice results in animals
that exhibit schizophrenia-relevant phenotypes (e.g., hyper-
activity, impaired working memory, and deficit in prepulse
inhibition) (Wen et al., 2010), the use of K252a (1) and inhibi-
tion of AAK1-mediated signaling may provide further insight
into the role of Nrg1 and ErbB4 in the pathogenesis of
psychotic illnesses. In addition a recent genome-wide asso-
ciation study of factors influencing the age of onset of Par-
kinson’s disease (OMIM 168600) identified single nucleotide
polymorphisms in an intron of the AAK1 gene, highlighting
a potentially important role for regulation of neurotrophic
factor signaling in other CNS disorders (Latourelle et al.,
2009). Thus, the integrative chemical genomic andproteomic
approach described here has the potential to be broadly
applicable to the identification of functionally important
targets and mechanisms for disease intervention.
EXPERIMENTAL PROCEDURES
Materials
PC12 cells (subclone Neuroscreen-1) were obtained from Cellomics (now
Thermo Fisher Scientific, Pittsburgh, PA). PC12-ErbB4-GFP and PC12-GFP
stable cell lines were generated previously (Kuai et al., 2010). Antibodies
used were: rabbit anti-ErbB4 c-18, rabbit anti-phospho-ErbB4 (Santa Cruz
Biotechnology, Santa Cruz, CA; #SC283, #SC33040); rabbit anti-phospho-
p42/44 MAPK, rabbit anti-p42 MAPK, rabbit anti-PKCa, rabbit anti-PKC3,
rabbit anti-GSK3b (Cell Signaling Technology; #9106, #4695, #2056, #2683,
and #9315, respectively); and mouse anti-actin (Sigma; A1798). AAK1 rabbit
anti-sera and the D-AID AAK1-GST construct were obtained from Dr. Sean
D. Conner (University of Minnesota, Minneapolis, MN,). The EGF domain of
Nrg1b1 (corresponding to amino acid residues 176–246 of neuregulin-1b1)
was expressed and purified from E. coli (R&D Systems; #396-HB-CF) and
reconstituted in phosphate-buffered saline (PBS) with 0.1% bovine serum
albumin as a nonspecific carrier and frozen in aliquots at 20C. Murine 2.5S
Nerve growth factor (Promega; G5141) was reconstituted in PBS 0.1% bovine
serum albumin as a nonspecific carrier and frozen in aliquots at20C. siRNA
SmartPools for specified target genes (AAK1: L-105612-01; AP2M1: L-096180-
01; PKCa: L-080129-00;MAP2K4: L-084558-00;MAP2K2: L-088324-01), non-
targeting (D-001810-10), and DharmaFECT2 (T-2002-03) were purchased
from Dharmacon (Chicago, IL). Lentiviral shRNAs used are summarized in
Table S2. Hairpin sequences can be retrieved from http://broadinstitute.org/
genome_bio/trc/publicSearchForHairpinsForm.php.
Cell Culturing and Stable Cell Line Generation
PC12 cells were maintained in RPMI 1640 media (GIBCO; 22400) containing
10% heat-inactivated horse serum (GIBCO; 26050), 5% heat-inactivated fetal
bovine serum (GIBCO; 16140), and 1% penicillin/streptomycin (GIBCO;Chemistry & Biology 18,10378) referred to here as RPMI+. For PC12-ErbB4-GFP and PC12-GFP,
1% penicillin/streptomycin was replaced with 750 mg/ml gentamicin (GIBCO;
15750). Cells were passaged at 80%–90% confluency and incubated at
37C in 5%CO2. Media were changed every 3 days. PC12 cells were cotrans-
fected with pcDNA3-ErbB4-neomycin or pcDNA3-neomycin and pcDNA-GFP
using FuGene 6 transfection reagent (Roche Diagnostics; 11814443). Cells
that express the neomycin-resistant gene were selected and maintained in
same culture media with substitution of 750 mg/ml gentamicin. After 2 weeks
of gentamicin selection, cells were further selected by fluorescence-activated
cell sorting (FACS) using a MoFlo Cell Sorter (Dako, Denmark) of the top 5%
most strongly GFP-expressing cells. The expression of GFP in the resulting
cell population, PC12-ErbB4-GFP, and PC12-GFP was observed to be stable
for at least 50 passages.
Western Blotting and Silver Staining
Cells were lysed with RIPA buffer (Pierce Technology, Rockford, IL; 89901)
containing one tablet per 10 ml protease inhibitor cocktail Complete Mini
(Roche Applied Science; 11836153). For phosphoprotein analysis, Halt
Phosphatase Inhibitor Cocktail (Pierce Technology; 78415) was also included.
Cell lysates were cleared by centrifugation at 15,000 rpm for 30 min at 4C,
followed by addition of LDS sample buffer (Invitrogen; NP008) for direct anal-
ysis. Samples were separated using a 4%–12% gradient gel (Invitrogen) and
SDS-PAGE and transferred to a polyvinylidene difluoride (PVDF; Schleicher
& Schnell; 10413096) membrane in 25 mM Tris, 192 mM glycine, and 20%
methanol. The membrane was probed with specific primary antibodies
according to specified recipes provided by their venders and then horseradish
peroxidase-conjugated secondary antibody to mouse or rabbit IgG (GE
Healthcare, Piscataway, NJ; NA934V and NA931V). Target protein bands
were detected with SuperSignal West FemtoMax Sensitivity Substrate (Pierce
Technology; 34095). Silver staining was performed according to manufacturer
protocol (Invitrogen; SilverQuest Silver Staining Kit, LC6070).
Lentiviral shRNA Knockdown of Target Genes
Lentiviral shRNA experiments were performed as previously described (Moffat
et al., 2006) with modifications compatible with the use of automatic neurite
detection algorithms. Cells were typically seeded at a density of 4000 cells/
cm2 and incubated for 12 hr. Lentiviruses were added at a multiplicity of infec-
tion (MOI) 1, and the plate was centrifuged at 2000 rpm for 20 min before
continued incubation in 37C. The cells were incubated for 24 hr at 37C in
5% CO2 and treated with neurotrophic factors together with 2 mg/ml puro-
mycin for neuritogenesis measurement after 48 hr, or directly lysed for western
blot analysis.
siRNA Knockdown of Target Genes
Cells were typically seeded at a density of 4000 cells/cm2 and incubated for
12 hr. siRNAs were prepared as a 1 mM solution in serum-free medium, and
DharmaFECT2 was diluted 1:50 (v/v) with serum-free medium. Both solutions
were incubated at room temperature for 5 min before mixing thoroughly and
incubated for an additional 20 min. The transfection mix was then added to
cell cultures at 1:5 (v/v). The cells were incubated for 24 hr at 37C in 5%
CO2 and treated with neurotrophic factors or directly lysed for western blot
analysis.
Cell Imaging and Neurite Measurements
Cells were seeded in black, clear bottom, tissue culture-treated 96-well (Corn-
ing; 3904) or 384-well (Corning; 3712) plates at typical density of 4000 cell/cm2
corresponding to approximately 1200 cells per well of a 96-well plate in 100 ml
of media and 300 cells per well of a 384-well plate in 40 ml of RPMI medium.
Even distribution of cells was achieved by a quick centrifuge at 500 rpm using
a tabletop centrifuge (Sorvall, LegendRT) and multiwell plate adaptors shortly
after cell seeding. Cells were then incubated for 12 hr followed by treatment
with growth factors or compounds as indicated. At specified time points, fluo-
rescent images were taken using an ImageXpress 5000A or ImageXpress
Micro automated microscopy (Molecular Devices) either manually or laser-
based autofocus with a Nikon 43 objective (ELWD S Fluor/0.20 NA) and an
image acquisition time of 150 ms or as specified. Transmitted light images
were taken using an ImageXpress Micro (Molecular Devices) with an attached
transmitted light device with a Nikon 43 objective (ELWD S Fluor/0.20 NA).891–906, July 29, 2011 ª2011 Elsevier Ltd All rights reserved 903
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Devices) using the ‘‘Neurite Detection’’ analysis module. Cell bodies were
specified as pixel blocks of maximum width 40 mm, minimum area 200 mm2,
and pixel intensities 1000 U above local background. Neurites were specified
as linear objects with maximum width 3 mm and pixel intensities 500 U above
the local background of the object being measured.
SILAC Media Preparation and Cell Culture Conditions
We followed all standard SILACmedia preparation and labeling steps as previ-
ously described (Ong and Mann, 2006), except that 750 mg/ml gentamicin was
supplemented for maintenance of the transfected ErbB4 plasmid. ErbB4-
PC12 cells were grown in RPMI-labeling media, prepared as described above,
supplemented with 2 mM L-glutamine, and 10% dialyzed fetal bovine serum
plus antibiotics, in a humidified atmosphere with 5% CO2 in air. Cells were
grown for at least six cell divisions in labeling media.
Preparation of Affinity Matrices
See Supplemental Experimental Procedures.
Biochemical Enrichment with Small Molecule Affinity
Capture Probes
Separate cultures of ErbB4-PC12 cells SILAC labeled either with L-arginine
and L-lysine (light) or L-arginine-13C6 and L-lysine-
13C6-
15N2 (heavy) were
lysed in ice-chilled ModRIPA buffer (low-stringency [LS] buffer) containing
1% NP-40, 0.1% sodium deoxycholate, 150 mM NaCl, 1 mM EDTA, 50 mM
Tris (pH 7.5), and protease inhibitors (CompleteTM tablets; Roche Applied
Science, Indianapolis, IN). Lysates were vortexed intermittently while chilled
on ice for 10 min and clarified by spinning at 14,000 3 g. Protein concentra-
tions of light and heavy lysates were estimated with the Protein Assay Dye
Reagent Concentrate (Bio-Rad, Hercules, CA) and equalized.
For bead control SILAC-Target ID affinity pull-down experiments, 2 mg
of light ErbB4-PC12 lysate was incubated with 25 ml of 50% slurry of
empty bead, whereas 2 mg of heavy lysate was incubated with 25 ml of 50%
of either AC-K252a (‘‘active’’) or AC-K252a-Me (‘‘inactive’’) small molecule
affinity capture probes. In ‘‘inactive’’ K252a-Me versus ‘‘active’’ AC-K252a
experiments, two LS wash experiments were performed where the ModRIPA
lysis buffer was used to wash the pull-downs. These two sets of pull-downs
were performed in ‘‘forward’’ and ‘‘reverse’’ modes, with bait swapping using
the same sets of lysates and beads but swapping the respective combinations
of lysates-beads in the two replicate experiments. Affinity enrichments were
incubated overnight (16 hr) on an end-over-end rotator at 4C. Following
incubation the tubes were spun at 10003 g on a benchtop centrifuge to pellet
the beads. The supernatant was aspirated carefully. Beads were combined at
the first wash for subsequent washing steps. In the third experiment a wash
buffer (high stringency [HS]) containing ModRIPA and 0.2% SDS was used
to wash beads instead. After the third and final wash, beads were collected
by spinning at 1000 3 g, and the wash was aspirated, leaving approximately
20 ml of buffer in the tube.
One-Dimensional SDS-PAGE and Mass Spectrometric Analysis
Proteins were reduced and alkylated, on beads, in 2 mM DTT and 10 mM
iodoacetamide, respectively. One-part LDS buffer (Invitrogen) was added to
three-parts sample (including beads), and tubes were heated to 70C for
10 min. Proteins were resolved on a 4%–12% gradient, 1.5 mm thick Bis-
Tris gel with MES running buffer (NuPAGE; Invitrogen) and Coomassie stained
(Simply Blue; Invitrogen). Gel lanes were excised into six pieces and then
further cut into 1.5 mm cubes. The gel pieces were further destained in a solu-
tion containing 50% EtOH and 50% 50 mM ammonium bicarbonate, then
dehydrated in 100% EtOH before addition of sufficient trypsin (12.5 ng/ml) to
swell the gel pieces completely. An additional 100 ml of 50 mM ammonium
bicarbonate was added before incubating at 37C overnight on a thermomixer
(Eppendorf). Enzymatic digestion was stopped by the addition of 100 ml of 1%
TFA to tubes. A second extraction with 300 ml of 0.1% TFA was combined with
the first extract, and the peptides from each gel slice were cleaned up on C18
StageTips (Rappsilber et al., 2007). Peptides were eluted in 50 ml of 80%
acetonitrile/0.1% TFA and dried down in an evaporative centrifuge to remove
organic solvents. The peptides were then resuspended by vortexing in 7 ml of
0.1% TFA and analyzed by nanoflow-LCMS with an Agilent 1100 with auto-904 Chemistry & Biology 18, 891–906, July 29, 2011 ª2011 Elsevier Lsampler and a LTQ-Orbitrap. Peptides were resolved on a 10 cm column,
made in-house by packing a self-pulled 75 mm I.D. capillary, 15 mm tip
(P-2000 laser-based puller; Sutter Instruments) column with 3 mm Reprosil-
C18-AQ beads (Dr. Maisch GmbH, Ammerbuch-Entringen, Germany) with an
analytical flow rate of 200 nl/min and a 58 min linear gradient (0.57% B/min)
from 0.1% formic acid in water to 0.1% formic acid/90% acetonitrile. The run
time was 108 min for a single sample, including sample loading and column
reconditioning.
We used a mass spectrometry method with a master Orbitrap full scan
(60,000 resolution) and data-dependent LTQ MS/MS scans for the top five
precursors (excluding z = 1) from the Orbitrap scan. Each cycle was approxi-
mately 2 s long. We used MaxQuant (Cox and Mann, 2008) (v.1.0.12.31) with
Mascot (Matrix Science Ltd., London) for mass spectrometry peak identifica-
tion and quantification. We searched the IPI rat v3.52 (http://www.ebi.ac.uk)
with a decoy database search strategy including common contaminants like
BSA and proteolytic enzymes, with ±7 ppm and ±0.5 Da mass tolerance at
the precursor and fragment levels, respectively. The protein and peptide
false-discovery rate for protein identification was set at 0.01. Protein ratios
are reported only when two or more peptides were quantitated. Search
variables for SILAC were Arg-12C6 and Lys-
12C6
14N2 (light) or Arg-
13C6 and
Lys-13C6
15N2 (heavy), variable modifications were oxidized methionine and
acetylation of protein N termini, whereas only carbamidomethylated cysteines
were considered.
In Vitro Kinase Assays
Kinase assays were performed with the ADP-Glo Kinase Assay system
(Promega). For the AAK1 kinase assay, 3 ng/ml recombinant AAK1 (D-AID)
was incubated at room temperature with 300 mM of a custom synthetic
AP2M1 peptide substrate (QHQTKEEQSQITSQVT*GQIGWRREGIKYRR),
synthesized by the MIT Biopolymers Facility using standard methods, that
was based upon the sequence flanking the known AAK1 phosphorylation
site (Thr156; marked by asterisk) of rat AP2M1 (Olusanya et al., 2001), and
kinase inhibitors at designated concentrations in kinase assay buffer (25 mM
Tris, 10 mM MgCl2, 5 mM DTT, 0.2 units/ml Heparin, 0.1 mg/ml BSA, and
100 mM ATP) for 90 min, and the resulting ADP was detected following the
manufacturer’s instructions. For GSK3b, 3 ng/ml of kinase was incubated
with 10 mM primed phosphopeptide substrate (YRRAAVPPSPSLSRHSSPHQ
SpEDEEE) (Ojo et al., 2008). Other conditions were the same as for the
AAK1 kinase assay.
Fluorescently Labeled Nrg1
Alexa 594-Nrg1 was prepared using an Alexa 594 protein labeling kit (Invitro-
gen; A10239) following the vendor’s recommended protocol.
Confocal Imaging of ErbB4 and Nrg1 Internalization
PC12-GFP and PC12-ErbB4-GFP cells were incubated with 50 nM K252a
for 12 hr, then treated with Alexa 594-Nrg1 (100 ng/ml) for 30 min, and then
fixed with 4% paraformaldehyde, permeabilized, and stained with an anti-
ErbB4 antibody recognizing the extracellular domain (Lab Vision; MS-270), fol-
lowed by detection using an anti-mouse IgG-Alexa 488 (Invitrogen; A11001)
secondary antibody. Thirty minutes was determined by regular fluorescence
microscopy for minimum time allowing detection of internalization. Cells
were imaged using confocal microscopy with a 603 objective.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
four figures, and two tables and can be found with this article online at
doi:10.1016/j.chembiol.2011.03.017.
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